$GLSI News

Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate

Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026

Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial

Greenwich LifeSciences Receives Nasdaq Noncompliance Notice

Greenwich LifeSciences Receives Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences Receives Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences Reports 70%–80% Drop In Cancer Recurrence In Early Trial Data

Greenwich Lifesciences Used Its ATM Facility To Issue Shares Directly Into The Market At Prevailing Prices. Proceeds Raised In Q1 2026 Exceeded The Quarter's Cash Burn, Resulting In An Estimated Cash Balance Of About $10.5M As Of March 31

Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim

Greenwich LifeSciences Says Breast Cancer Therapy Could Double Patient Reach With New Patent Claims

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Greenwich LifeSciences Expands Breast Cancer Trial Across Major US Cancer Centers, Launches New Study Sites To Advance Cancer Recurrence Therapy

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Greenwich LifeSciences To Present Two Posters At AACR 2026, Including First FLAMINGO-01 Statistically Significant Immune Response Data

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Greenwich Lifesciences' Preliminary Update Shows A Continued Reduction In The Recurrence Rate In The Fully Enrolled, 250-patient, Open-label Non-HLA-A*02 Arm Of FLAMINGO-01

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences Says FDA Approves The First Commercial Lot Of GP2 Vials For Use In FLAMINGO-01 Study In U.S.

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Greenwich LifeSciences Says FLAMINGO 01 Patient Screen Rate Rose About 33% To Over 800 Per Year, With More Than 1,000 Screened And Non HLA A 02 Arm Fully Enrolled At 250 Patients